v3.25.1
Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Revenue $ 666,655 $ 93,855
Cost of sales 14,115 59,209
Research and development expenses: 88,937 92,679
Net income (loss) 518,646 (147,550)
Reportable Segment    
Segment Reporting Information [Line Items]    
Revenue 666,655 93,855
Cost of sales 14,115 59,209
Selling, general, and administrative expense 48,090 86,798
Other segment income (expense) 3,133 (2,719)
Net income (loss) 518,646 (147,550)
Employee and benefit expenses | Reportable Segment    
Segment Reporting Information [Line Items]    
Research and development expenses: 39,910 43,458
Facility and other research and development expenses | Reportable Segment    
Segment Reporting Information [Line Items]    
Research and development expenses: 29,089 22,824
Direct coronavirus vaccines | Reportable Segment    
Segment Reporting Information [Line Items]    
Research and development expenses: 18,059 26,061
Direct other vaccine development programs | Reportable Segment    
Segment Reporting Information [Line Items]    
Research and development expenses: $ 1,879 $ 336